Trials / Completed
CompletedNCT00055471
A Phase IIa. Open-label, Multicenter, Dose-escalation Study to Assess the Tolerability and Pharmacokinetics of ZD4054 (Zibotentan) Given Orally Once Daily in Subjects With Metastatic Prostate Cancer
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 22 (actual)
- Sponsor
- AstraZeneca · Industry
- Sex
- Male
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The primary purpose of this study is to determine the safest dose of ZD4054 (Zibotentan)in men with prostate cancer
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | ZD4054 10 mg | 1 x 10 mg oral tablets once daily |
| DRUG | ZD4054 15 mg | 1 x 10 mg + 2 x 2.5 mg oral tablets once daily |
| DRUG | ZD4054 22.5 mg | 2 x 10 mg + 2 x 2.5 mg oral tablets once daily |
Timeline
- Start date
- 2003-06-01
- Primary completion
- 2005-10-01
- Completion
- 2005-10-01
- First posted
- 2003-03-04
- Last updated
- 2012-10-31
- Results posted
- 2012-08-31
Locations
2 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT00055471. Inclusion in this directory is not an endorsement.